EMR Messaging Woes (4.11.2025)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
Read Article
📢Calling all paediatrics! #BSR25 is almost here - Check out our top paediatric highlights from a packed Annual Conference programme 🔗Read our latest blog now: https://t.co/8uJMiqg2fW https://t.co/PAASNk3ZuF
Links:
BSR @RheumatologyUK( View Tweet )
Prof Ian Giles will be covering a range of topics at this year's Rheumapreg Conference such as how immunologic changes and placental dysfunction cause adverse outcomes in rheumatic disease pregnancies.
View the full prgramme and learn more: https://t.co/tjiycjKJ8i https://t.co/FugHvtm8fY
BSR @RheumatologyUK( View Tweet )
Uveitis Risk with Slow Adalimumab Weaning
Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort analysis indicated. https://t.co/K8n9MFaTzd
Dr. John Cush @RheumNow( View Tweet )
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/fw8wcuS48E https://t.co/LgS3Sxy7gd
Dr. John Cush @RheumNow( View Tweet )
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/tnYgg6MNXp https://t.co/zJor1oTFfD
Dr. John Cush @RheumNow( View Tweet )
Uveitis Risk with Slow Adalimumab Weaning
MedPage Today
Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort analysis indicated.
Read Article
🎉 Today's Annual Scientific Conference kicked off with The CARRA Registry Retreat! The retreat brought together physician-PIs, research coordinators, research managers and patients/caregivers involved with the CARRA Registry. 💙 #CARRA2025 #pedsrheum https://t.co/GYYHAjsIdK
CARRA @carrainc( View Tweet )
1st Line Biologics vs csDMARDs in Adult Still's Disease
A German multicentre, retrospective study assessed the first-line efficacy of biologics and conventional synthetic DMARD therapy in patients with adult-onset Still's disease and found biologic agents were significantly better with sustained, event-free remissions and fewer complications.
Read Article
Worse Outcomes in HLA-B27+ JIA
MedPage Today
Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study.
Read Article
Autoimmune Disease Impact Report
Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: rheumatoid arthritis, multiple sclerosis,
Read Article
Targeting Obesity in Rheumatic Disease Patients
Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese.
Read Article
ERA, APPs, & Alpha GAL (3.21.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Listen in for 2 new case questions - Ask Cush Anything.
Read Article
PAFLAR Guidelines for Polyarticular Juvenile Idiopathic Arthritis
The Pediatric African League against Rheumatism (PAFLAR) initiative has published its guidelines for the diagnosis and treatment of polyarticular juvenile idiopathic arthritis (pJIA
Cochrane review of TNF inhib. in #JIA shows TNFi efficacy, but uncertainty about LT safety, pain, function, & Dz control - esp compared to MTX. 9 studies, 678 JIApts, age 8-15 yrs (80% F), Dz duration 0.8-6.7 yrs. Withdrawls 1% v 3%; Serious AE 6% v 7% (PBO vs TNFi).… https://t.co/i35m5uzG1m https://t.co/VzJN9PmmMh
Dr. John Cush @RheumNow( View Tweet )
Opioid Deaths are Down (2.28.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week!
Read Article
Cochrane review of TNF inhib. in #JIA shows TNFi efficacy, but uncertainty about LT safety, pain, function, & Dz control - esp compared to MTX. 9 studies, 678 JIApts, age 8-15 yrs (80% F), Dz duration 0.8-6.7 yrs. Withdrawls 1% v 3%; Serious AE 6% v 7% (PBO vs TNFi).… https://t.co/twmYfFg702 https://t.co/hG3j4sMPr9
Dr. John Cush @RheumNow( View Tweet )
Do infections lead to Kawasaki Dz (KD)? Swedish registry study of 1774 KD vs 17 731 controls. +Hx of Infx incr risk of KD (OR 2.3; 2.0 to 2.5) - mostly Resp, skin, GU & GI Infx. Infxns usually clustered before KD Dx (OR 5.1 15–28d; OR 1.3 6-12 mos prior KD. More infx = more KD… https://t.co/V9zbcmJdKv https://t.co/Evl3rtCxUO
Dr. John Cush @RheumNow( View Tweet )
At RWCS 2025, Dr. Susan Shenoi aptly noted the prevalence of multisystem inflammatory syndrome in children (MIS-C) has declined significantly. Does this indicated herd immunity or the decline of community SARS-CoV-2 (or both)? @ShenoiSusan https://t.co/vY01VDkNVl… https://t.co/c8Qu4OqBSh https://t.co/yZAoRcG6LN
Dr. John Cush @RheumNow( View Tweet )
NRMP Publishes 2025 Match Results. Rheumatology Stats:
- Ped Rheum #5 in # U.S. DO grads (30%)
- Adult Rheum #5 in Intl Med school grads (34%)
- Adult: 3/132 progr. went unfilled (Ped: 20/36 unfilled)
https://t.co/AsfOZMydMK https://t.co/Dim3hCLzXC
Dr. John Cush @RheumNow( View Tweet )
Survey on Corticosteroid (CS) use in PFAPA syndrome included 144 MDs (67% pedi-Rheums); 92% use CS in PFAPA flares. 42% expected a response w/in 12 hrs. 31% use CS ‘routinely. Med literature cites Prednisone as most preferred CS (48%). Response to CS ~ 95% https://t.co/V1wkhNaNAP https://t.co/YILAlKrUcQ
Dr. John Cush @RheumNow( View Tweet )
BSR Guideline on Management of Sjögren disease
The British Society for Rheumatology has published its guideline for the management of adult and juvenile onset Sjogren's disease.
https://t.co/UJOvb937lk https://t.co/P77h91nPuN
Dr. John Cush @RheumNow( View Tweet )
Dannish study of 1 million infants, exposed vs unexposed to systemic glucocorticoids shows prenatal GC exposure assoc w/ higher risk of autism (RR 1.5), intellectual disability (1.3), ADHD (1.3), mood/anxiety (1.3). Same risk for 290K mothers w/ autoimmune/inflamm Dz… https://t.co/bXL3YqCIYZ https://t.co/psNVENXRPs
Dr. John Cush @RheumNow( View Tweet )
BSR Guideline on Management of Sjögren disease
The British Society for Rheumatology has published its guideline for the management of adult and juvenile onset Sjogren's disease.
This guideline is an update to the 2017 guideline and is based on medical literature review focused on 19 clinical questions. While most of the
Read Article
Quick study of Henoch-Schönlein Purpura (HSP) in Children: An Overview https://t.co/LPFFDIeJPA https://t.co/PlTD0fOR2E
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
